Literature DB >> 8655920

Doppler echocardiographic patterns in patients with acromegaly.

M Terzolo1, L Avonto, C Matrella, R Pozzi, S Luceri, G Borretta, F Pecchio, G Ugliengo, G P Magro, G Reimondo.   

Abstract

Cardiovascular problems have long been recognized as responsible for an increased morbidity and mortality in patients with acromegaly. The aim of the present study was to evaluate echocardiographically the prevalence of cardiomyopathy in a cohort of acromegalic patients and to analyze the results in relation to demographic, clinical and hormonal data. This study, a retrospective controlled clinical trial, was performed in 25 acromegalic patients, 12 men and 13 women aged 26-66 years (mean: 52.6). Fifteen patients had an active disease, 10 were cured by previous pituitary surgery. The same echocardiographic parameters were analyzed in 50 healthy subjects aged 30-70 years (mean: 51.4). Serum GH was determined on at least 4 samples drawn over 24 hours and plasma IGF-I on a single point. Standardized parameters of diastolic and systolic function were evaluated by real-time Doppler echocardiography. Twelve patients with active acromegaly underwent also 48-hour ECG registering. Left ventricular (LV) hypertrophy was found in 14/25 patients (56%). No difference was found between patients with active disease (53%) and patients with cured acromegaly (60%). LV mass index was significantly increased in acromegalics in comparison with healthy subjects (137 +/- 43 g/m2 vs 96 +/- 16 g/m2, p < 0.01) and also the indices of LV diastolic function were significantly impaired. Asymmetric septal hypertrophy was found only in one patient. Hypertension was detected in 9/25 patients (36%) without difference between patients with active or cured disease (40% vs 30%, NS). No significant correlation was found between hormonal or clinical data and echocardiographic findings. During Holter monitoring, heart rate of acromegalics was not significantly different from that of controls (78 +/- 12 bpm vs 72 +/- 10 bpm, NS) and only isolated supraventricular or ventricular premature complexes (Lown class 1) were detected. In conclusion, this study provides evidence of subclinical LV dysfunction in acromegaly in the absence of other known causes of heart disease and no significant difference in echocardiographic pattern was apparent between active or cured acromegalics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8655920     DOI: 10.1007/BF03349779

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  Acromegaly.

Authors:  G J HAMWI; T G SKILLMAN; K C TUFTS
Journal:  Am J Med       Date:  1960-10       Impact factor: 4.965

2.  Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly.

Authors:  C M Ritchie; B Sheridan; R Fraser; D R Hadden; A L Kennedy; J Riddell; A B Atkinson
Journal:  Q J Med       Date:  1990-08

3.  Regression of left ventricular hypertrophy in treated hypertensive patients with dilevalol and metoprolol--a double blind randomized study.

Authors:  S P Glasser; D K Koehn; R Powell
Journal:  J Clin Pharmacol       Date:  1989-09       Impact factor: 3.126

4.  Evidence of subclinical heart muscle dysfunction in acromegaly.

Authors:  E A Jonas; J F Aloia; F J Lane
Journal:  Chest       Date:  1975-02       Impact factor: 9.410

5.  The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study.

Authors:  L Thuesen; S E Christensen; J Weeke; H Orskov; P Henningsen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-06       Impact factor: 3.478

6.  Acromegalic cardiopathy: a left ventricular scintigraphic study.

Authors:  N Sicolo; F Bui; M Sicolo; L Varotto; C Martini; C Macor; G Federspil
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

7.  Relation of endocrine and cardiac findings in acromegalics.

Authors:  G Kahaly; C Stover; J Beyer; S Mohr-Kahaly
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

8.  Heart size and function in acromegaly.

Authors:  H M Mather; M J Boyd; J S Jenkins
Journal:  Br Heart J       Date:  1979-06

9.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

Authors:  B Merola; A Cittadini; A Colao; D Ferone; S Fazio; D Sabatini; B Biondi; L Saccá; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.

Authors:  M J Lim; A L Barkan; A J Buda
Journal:  Ann Intern Med       Date:  1992-11-01       Impact factor: 25.391

View more
  4 in total

1.  Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features.

Authors:  M Terzolo; C Matrella; A Boccuzzi; S Luceri; M Borriero; G Reimondo; A Pia; E Rovero; P Paccotti; A Angeli
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain.

Authors:  I C M Volschan; L Kasuki; C M S Silva; M L Alcantara; R M Saraiva; S S Xavier; M R Gadelha
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 3.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

4.  Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly.

Authors:  Juan Francisco Martín-Rodríguez; Ainara Madrazo-Atutxa; Eva Venegas-Moreno; Pedro Benito-López; María Ángeles Gálvez; David A Cano; Francisco J Tinahones; Elena Torres-Vela; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.